This is a randomized, double-blind, placebo-controlled, sequential design, multicentre study
in patients with moderately impaired systolic function undergoing CABG surgery. Twenty four
(24) patients scheduled for elective bypass surgery will be randomized (up to approximately
33 patients if replacements are needed). The objective is to investigate safety and
tolerability of AZD8601 following epicardial injection in patients undergoing Coronary Artery
Bypass Grafting (CABG) surgery with moderately impaired systolic function. At Visit 3
patients will receive either AZD8601 or placebo as epicardial injections and will then be
followed up at 14 days (telephone visit) and 1, 3 and 6 months (on-site) post-surgery.